WO2008060788A3 - Compositions, methods, and devices for treating liver disease - Google Patents

Compositions, methods, and devices for treating liver disease Download PDF

Info

Publication number
WO2008060788A3
WO2008060788A3 PCT/US2007/081142 US2007081142W WO2008060788A3 WO 2008060788 A3 WO2008060788 A3 WO 2008060788A3 US 2007081142 W US2007081142 W US 2007081142W WO 2008060788 A3 WO2008060788 A3 WO 2008060788A3
Authority
WO
WIPO (PCT)
Prior art keywords
liver disease
compositions
methods
devices
treating liver
Prior art date
Application number
PCT/US2007/081142
Other languages
French (fr)
Other versions
WO2008060788A2 (en
Inventor
Martin L Yarmush
Biju Parekkadan
Original Assignee
Gen Hospital Corp
Massachusetts Inst Technology
Martin L Yarmush
Biju Parekkadan
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Gen Hospital Corp, Massachusetts Inst Technology, Martin L Yarmush, Biju Parekkadan filed Critical Gen Hospital Corp
Priority to EP07868423A priority Critical patent/EP2076116A4/en
Publication of WO2008060788A2 publication Critical patent/WO2008060788A2/en
Publication of WO2008060788A3 publication Critical patent/WO2008060788A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M1/00—Suction or pumping devices for medical purposes; Devices for carrying-off, for treatment of, or for carrying-over, body-liquids; Drainage systems
    • A61M1/34—Filtering material out of the blood by passing it through a membrane, i.e. hemofiltration or diafiltration
    • A61M1/3472—Filtering material out of the blood by passing it through a membrane, i.e. hemofiltration or diafiltration with treatment of the filtrate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/28—Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M1/00—Suction or pumping devices for medical purposes; Devices for carrying-off, for treatment of, or for carrying-over, body-liquids; Drainage systems
    • A61M1/34—Filtering material out of the blood by passing it through a membrane, i.e. hemofiltration or diafiltration
    • A61M1/3472—Filtering material out of the blood by passing it through a membrane, i.e. hemofiltration or diafiltration with treatment of the filtrate
    • A61M1/3486—Biological, chemical treatment, e.g. chemical precipitation; treatment by absorbents
    • A61M1/3489—Biological, chemical treatment, e.g. chemical precipitation; treatment by absorbents by biological cells, e.g. bioreactor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M1/00—Suction or pumping devices for medical purposes; Devices for carrying-off, for treatment of, or for carrying-over, body-liquids; Drainage systems
    • A61M1/36—Other treatment of blood in a by-pass of the natural circulatory system, e.g. temperature adaptation, irradiation ; Extra-corporeal blood circuits
    • A61M1/3687—Chemical treatment
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M1/00—Suction or pumping devices for medical purposes; Devices for carrying-off, for treatment of, or for carrying-over, body-liquids; Drainage systems
    • A61M1/36—Other treatment of blood in a by-pass of the natural circulatory system, e.g. temperature adaptation, irradiation ; Extra-corporeal blood circuits
    • A61M1/3687—Chemical treatment
    • A61M1/3689—Chemical treatment by biological cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12M—APPARATUS FOR ENZYMOLOGY OR MICROBIOLOGY; APPARATUS FOR CULTURING MICROORGANISMS FOR PRODUCING BIOMASS, FOR GROWING CELLS OR FOR OBTAINING FERMENTATION OR METABOLIC PRODUCTS, i.e. BIOREACTORS OR FERMENTERS
    • C12M29/00—Means for introduction, extraction or recirculation of materials, e.g. pumps
    • C12M29/16—Hollow fibers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0652—Cells of skeletal and connective tissues; Mesenchyme
    • C12N5/0662—Stem cells
    • C12N5/0663—Bone marrow mesenchymal stem cells (BM-MSC)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/067—Hepatocytes
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • G01N33/5067—Liver cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • G01N33/5073—Stem cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2502/00—Coculture with; Conditioned medium produced by
    • C12N2502/13—Coculture with; Conditioned medium produced by connective tissue cells; generic mesenchyme cells, e.g. so-called "embryonic fibroblasts"
    • C12N2502/1352—Mesenchymal stem cells
    • C12N2502/1358—Bone marrow mesenchymal stem cells (BM-MSC)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/08—Hepato-biliairy disorders other than hepatitis
    • G01N2800/085—Liver diseases, e.g. portal hypertension, fibrosis, cirrhosis, bilirubin

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cell Biology (AREA)
  • Hematology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Vascular Medicine (AREA)
  • Zoology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Anesthesiology (AREA)
  • Genetics & Genomics (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Developmental Biology & Embryology (AREA)
  • Medicinal Chemistry (AREA)
  • Urology & Nephrology (AREA)
  • General Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Cardiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Pathology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Toxicology (AREA)

Abstract

Described are compositions and methods for treating liver disease, e.g., acute liver disease, using bone marrow-derived stem cells and bone marrow-derived stem cell conditioned media.
PCT/US2007/081142 2006-10-11 2007-10-11 Compositions, methods, and devices for treating liver disease WO2008060788A2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
EP07868423A EP2076116A4 (en) 2006-10-11 2007-10-11 Compositions, methods, and devices for treating liver disease

Applications Claiming Priority (8)

Application Number Priority Date Filing Date Title
US85077806P 2006-10-11 2006-10-11
US60/850,778 2006-10-11
US85123406P 2006-10-12 2006-10-12
US60/851,234 2006-10-12
US92313807P 2007-04-12 2007-04-12
US60/923,138 2007-04-12
US99531607P 2007-09-26 2007-09-26
US60/995,316 2007-09-26

Publications (2)

Publication Number Publication Date
WO2008060788A2 WO2008060788A2 (en) 2008-05-22
WO2008060788A3 true WO2008060788A3 (en) 2008-12-04

Family

ID=39402354

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2007/081142 WO2008060788A2 (en) 2006-10-11 2007-10-11 Compositions, methods, and devices for treating liver disease

Country Status (7)

Country Link
US (3) US8172784B2 (en)
EP (2) EP2076116A4 (en)
DK (1) DK2578081T3 (en)
ES (1) ES2583371T3 (en)
PL (1) PL2578081T3 (en)
PT (1) PT2578081E (en)
WO (1) WO2008060788A2 (en)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0329449D0 (en) * 2003-12-19 2004-01-28 Omnicyte Ltd Stem cells
US8172784B2 (en) 2006-10-11 2012-05-08 The General Hospital Corporation Compositions, methods, and devices for treating liver disease
US20110190680A1 (en) 2008-09-29 2011-08-04 Yoram Vodovotz Self-Regulating Device for Modulating Inflammation
GB0818725D0 (en) * 2008-10-13 2008-11-19 Habib Nagy A Pharmaceutical composition
WO2011156338A2 (en) 2010-06-07 2011-12-15 University Of Pittsburgh - Of The Commonwealth System Of Higher Education Methods for modeling hepatic inflammation
CN102641297B (en) * 2011-02-21 2016-02-24 杨子江 Preparation of the ischemic disease that treatment Peripheral atherosclerosis causes and preparation method thereof
CN102641292B (en) * 2011-02-21 2015-11-25 杨子江 Preparation of short blood vessel and perienchyma's reparation or regeneration and preparation method thereof
CN102641293B (en) * 2011-02-21 2016-02-24 杨子江 Preparation being used for the treatment of ischemic cerebrovascular and preparation method thereof
ES2629502T3 (en) 2011-03-11 2017-08-10 Children's Medical Center Corporation Methods and compositions related to mesenchymal stem cell exosomes
EP2508607A1 (en) * 2011-04-07 2012-10-10 Helmholtz-Zentrum für Infektionsforschung GmbH Medicament for liver regeneration and for treatment of liver failure
ES2526816B1 (en) * 2013-06-14 2015-10-27 Fundación Pública Andaluza Progreso Y Salud Compositions for the treatment of liver damage
DK3016665T3 (en) 2013-07-05 2019-11-25 Univ Catholique Louvain CONDITIONED MEDIUM FROM HUMAN ADULT LIVER STEM CELLS AND ITS USE IN THE TREATMENT OF HEALTH DISEASES
AU2015264519B2 (en) 2014-05-18 2021-01-28 Children's Medical Center Corporation Methods and compositions relating to exosomes
ES2573354B1 (en) * 2014-11-06 2017-03-24 Servicio Andaluz De Salud Lysenchymal stem cell lysates for the treatment of skeletal muscle lesions
EP3277297B1 (en) * 2015-04-01 2021-07-28 SanBio, Inc. Methods and compositions for stimulation of cell proliferation and provision of biologically active mixtures of fgf2 isoforms
US11291689B2 (en) 2015-06-03 2022-04-05 Aelan Cell Technologies, Inc. Methods and devices for the production and delivery of beneficial factors from adipose-derived stem cells
US20180185446A1 (en) * 2015-06-15 2018-07-05 Vital Therapies, Inc. Composition and method for inducing anti-apoptosis, survival or proliferation of a cell
US20180220642A1 (en) * 2015-07-29 2018-08-09 Indiana University Research And Technology Corporation Materials and methods for treating and evaluating ischemic and/or reperfusion-injured tissue and/or tissue susceptible to same
US10328122B2 (en) * 2015-09-15 2019-06-25 Zhejiang University Method of treating fulminant hepatic failure using DLL4 cytokine
CN117496638A (en) 2016-08-02 2024-02-02 天使集团股份有限公司 Inspection system and management system
US20190350192A1 (en) * 2016-10-28 2019-11-21 Vital Therapies, Inc. Use of conditioned media from extracorporeal blood detoxifying system to supplement organ perfusion solutions
JP6950887B2 (en) * 2017-04-28 2021-10-13 米満　吉和 Extracorporeal artificial liver and equipment for extracorporeal artificial liver or hepatocyte culture
GB2568928B (en) * 2017-12-01 2023-03-08 Young Cell Biomedical Tech Inc Neuroprotective composition, preparation process thereof and medical uses thereof
GB2618001B (en) * 2018-02-20 2024-01-31 Emulate Inc Human microphysiological cell system for liver disease
JP2022512953A (en) * 2018-11-09 2022-02-07 フィジーン、エルエルシー Means and methods to prevent or reverse aging
AU2020388572A1 (en) * 2019-11-20 2022-05-26 Alkahest, Inc. Blood plasma fractions for use in liver regeneration
EP4036221A1 (en) * 2021-01-29 2022-08-03 Baer, Hans Ulrich Method for stimulating cell growth and proliferation of cells of interest, and method for preparing a liver or pancreas implant
CN113016778A (en) * 2021-02-08 2021-06-25 广东乾晖生物科技有限公司 Isolated organ perfusion preservation system based on mesenchymal stem cells
CN113082337A (en) * 2021-02-23 2021-07-09 广东乾晖生物科技有限公司 Biological artificial liver support system based on placenta mesenchymal stem cell bioreactor
CN115725708A (en) * 2021-08-30 2023-03-03 四川大学 Method for detecting nucleotide by using biological Hermite

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5605835A (en) * 1988-05-23 1997-02-25 Regents Of The University Of Minnesota Bioreactor device with application as a bioartificial liver

Family Cites Families (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4522811A (en) 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
US4833083A (en) * 1987-05-26 1989-05-23 Sepragen Corporation Packed bed bioreactor
US5602026A (en) * 1988-10-14 1997-02-11 The General Hospital Corporation Culturing liver cells between two supports
DE69118690T2 (en) * 1990-05-16 1997-01-09 Baylor College Medicine A PERMANENT HUMAN HEPATOGENIC CELL LINE AND ITS USE IN SUPPORTING LIVER FUNCTION
US5270192A (en) 1991-02-07 1993-12-14 Monsanto Company Biological artificial liver
US5549674A (en) * 1992-03-02 1996-08-27 The Regents Of The University Of Michigan Methods and compositions of a bioartificial kidney suitable for use in vivo or ex vivo
EP0784499A4 (en) 1992-09-11 2000-03-29 Xenogenex Inc Artificial liver apparatus and method
US5866420A (en) * 1993-10-08 1999-02-02 The United States Of America As Represented By The Secretary Of Agriculture Artificial liver device
US6472200B1 (en) 1999-07-23 2002-10-29 Yissum Research Development Company Of The Hebrew University Of Jerusalem Device and method for performing a biological modification of a fluid
EP0866849B1 (en) * 1995-10-06 2004-08-18 Academisch Ziekenhuis Bij De Universiteit Van Amsterdam Solid support for use in cell cultivation, especially for the cultivation of liver cells, biological reactor containing said solid support and the use thereof in a bio-artificial liver system
US6287558B1 (en) 1997-08-01 2001-09-11 Biohybrio Technologies Llc Devices containing cells or tissue and an agent that inhibits damage by a host cell molecule
US6429012B1 (en) 1997-10-06 2002-08-06 Viacell, Inc. Cell population containing non-fetal hemangioblasts and method for producing same
AUPP108597A0 (en) * 1997-12-22 1998-01-22 Sheil, A G R Prof. Liver support system
AU755888B2 (en) 1998-03-18 2003-01-02 Mesoblast International Sarl Mesenchymal stem cells for prevention and treatment of immune responses in transplantation
US6060364A (en) * 1999-03-02 2000-05-09 Advanced Micro Devices, Inc. Fast Mosfet with low-doped source/drain
DE60031966T2 (en) * 1999-04-23 2007-09-13 Renamed Biologics, Inc. EXTRACORPORAL CIRCULATION
US7759113B2 (en) 1999-04-30 2010-07-20 The General Hospital Corporation Fabrication of tissue lamina using microfabricated two-dimensional molds
US6372494B1 (en) 1999-05-14 2002-04-16 Advanced Tissue Sciences, Inc. Methods of making conditioned cell culture medium compositions
MXPA01013423A (en) * 1999-06-21 2002-12-05 Gen Hospital Corp Cell culture systems and methods for organ assist devices.
US6562616B1 (en) * 1999-06-21 2003-05-13 The General Hospital Corporation Methods and devices for cell culturing and organ assist systems
US6861001B2 (en) * 1999-12-02 2005-03-01 The General Hospital Corporation Methods for removal, purification, and concentration of viruses, and methods of therapy based thereupon
PT1261694E (en) * 2000-02-26 2008-04-03 Artecel Inc Pleuripotent stem cells generated from adipose tissue-derived stromal cells and uses thereof
AU2002213191B2 (en) 2000-10-12 2006-06-01 Renal Solutions, Inc. Devices and methods for body fluid flow control in extracorporeal fluid treatments
US7311905B2 (en) 2002-02-13 2007-12-25 Anthrogenesis Corporation Embryonic-like stem cells derived from post-partum mammalian placenta, and uses and methods of treatment using said cells
EP1367899A4 (en) 2001-02-14 2004-07-28 Leo T Furcht Multipotent adult stem cells, sources thereof, methods of obtaining and maintaining same, methods of differentiation thereof, methods of use thereof and cells derived thereof
US6582955B2 (en) 2001-05-11 2003-06-24 Spectrum Laboratories, Inc. Bioreactor with application as blood therapy device
US6607501B2 (en) * 2001-05-14 2003-08-19 Reynolds G. Gorsuch Process and apparatus for utilization of in vivo extracted plasma with tissue engineering devices, bioreactors, artificial organs, and cell therapy applications
US6620630B2 (en) 2001-09-24 2003-09-16 Extraction Systems, Inc. System and method for determining and controlling contamination
US20050008626A1 (en) * 2001-12-07 2005-01-13 Fraser John K. Methods of using adipose tissue-derived cells in the treatment of cardiovascular conditions
US6855542B2 (en) 2001-12-21 2005-02-15 Organogenesis Inc. Chamber with adjustable volume for cell culture and organ assist
AU2003228348A1 (en) * 2002-03-20 2003-10-08 John T. Fassett Induction of hepatocyte proliferation in vitro by inhibition of cell cycle inhibitors
US7160719B2 (en) * 2002-06-07 2007-01-09 Mayo Foundation For Medical Education And Research Bioartificial liver system
US8603462B2 (en) 2003-04-01 2013-12-10 University Of Utah Research Foundation Stem-cell, precursor cell, or target cell-based treatment of multi-organ failure and renal dysfunction
KR20060065712A (en) * 2003-08-27 2006-06-14 가부시키가이샤 레노메딕스 켄큐쇼 Method of differentiating mesenchymal stem cell into liver cell and artificial human liver cell
WO2005074657A2 (en) 2004-02-02 2005-08-18 The General Hospital Corporation Modified organ support devices
US7622108B2 (en) 2004-04-23 2009-11-24 Bioe, Inc. Multi-lineage progenitor cells
US7670596B2 (en) 2004-04-23 2010-03-02 Bioe, Inc. Multi-lineage progenitor cells
CA2564859C (en) * 2004-04-27 2013-04-09 Vital Therapies, Inc. Metabolic detoxification system and method
AU2005302469A1 (en) 2004-10-28 2006-05-11 Medivas, Llc Bioactive wound dressings and implantable devices and methods of use
WO2006121445A2 (en) 2005-05-10 2006-11-16 United States Of America Department Of Veteran's Affairs Therapy of kidney diseases and multiorgan failure with mesenchymal stem cells and mesenchymal stem cell conditioned media
US20070065415A1 (en) 2005-09-16 2007-03-22 Kleinsek Donald A Compositions and methods for the augmentation and repair of defects in tissue
AU2006332679A1 (en) * 2005-12-29 2007-07-12 Anthrogenesis Corporation Co-culture of placental stem cells and stem cells from a second source
US8172784B2 (en) 2006-10-11 2012-05-08 The General Hospital Corporation Compositions, methods, and devices for treating liver disease

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5605835A (en) * 1988-05-23 1997-02-25 Regents Of The University Of Minnesota Bioreactor device with application as a bioartificial liver

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
QIHAO ET AL.: "Spheroid Formation and Differentiation into Hepatocyte-Like Cells of Rat Mesenchymal Stem Cell Induced by Co-Culture with Liver Cells", DNA AND CELL BIOLOGY, vol. 26, no. 7, 2007, pages 497 - 503, XP008109874 *
TAKEDA ET AL.: "Availability of Bone Marrow Stromal Cells in Three-Dimensional Coculture with Hepatocyte and Transplantation into Liver-Damaged Mice", JOURNAL OF BIOSCIENCE AND BIOENGINEERING, vol. 100, no. 1, 2005, pages 77 - 81, XP005046482 *

Also Published As

Publication number Publication date
US8172784B2 (en) 2012-05-08
EP2578081A3 (en) 2013-04-24
EP2076116A4 (en) 2010-04-07
EP2578081A2 (en) 2013-04-10
PL2578081T4 (en) 2016-09-30
US20120225130A1 (en) 2012-09-06
DK2578081T3 (en) 2016-06-27
US20080145442A1 (en) 2008-06-19
WO2008060788A2 (en) 2008-05-22
PL2578081T3 (en) 2016-09-30
PT2578081E (en) 2016-06-17
ES2583371T3 (en) 2016-09-20
US20160331784A1 (en) 2016-11-17
EP2578081B1 (en) 2016-03-09
US10363276B2 (en) 2019-07-30
EP2076116A2 (en) 2009-07-08

Similar Documents

Publication Publication Date Title
WO2008060788A3 (en) Compositions, methods, and devices for treating liver disease
WO2008155659A3 (en) Compositions for preventing or treating skin defects and methods of use thereof
IL179919A0 (en) Neural stem cells, compositions containing the same and methods for promoting the division thereof
WO2007062188A3 (en) Activin-actriia antagonists and uses for promoting bone growth
HK1125395A1 (en) Interpenetrating networks, and related methods and compositions
WO2007146965A3 (en) Compounds for the treatment of periodontal disease
WO2008036374A3 (en) Allogeneic stem cell transplants in non-conditioned recipients
WO2007143204A3 (en) Compositions and methods for modifying cell surface glycans
EP1963500A4 (en) Compositions comprising oriented, immobilized macromolecules and methods for their preparation
IL233634A0 (en) Methods, compositions, and kits for the treatment of medical conditions
ZA200800970B (en) Gene disruptions, compositions and methods relating thereto
WO2009007852A3 (en) Multipotent/pluripotent cells and methods
GB0820190D0 (en) Tissue excision tool, kits and methods of using the same
WO2007125420A3 (en) Stem cells derived from bone marrow for tissue regeneration
IL211089A0 (en) Compositions and methods for cell killing
EP1937815A4 (en) Methods and compositions for modulating tumor cell activity
EP1920062A4 (en) Methods and compositions for growth of hydrocarbons in botryococcus sp.
BRPI0719272A2 (en) ENZYME COMPOSITION, AND METHOD FOR PREPARING AN ENZYME COMPOSITION.
WO2008027600A3 (en) Imatinib compositions
EP1924606A4 (en) Devices, compositions and methods for the protection and repair of cells and tissues
WO2008094945A3 (en) Compounds and methods for modulating protein expression
EP1871914A4 (en) Methods and compositions for introducing biopolymers into cells
ZA200805080B (en) Methods and compositions for expanding T regulatory cells
EP2058394A4 (en) Method for designing mutated enzyme, method for preparing the same and mutated enzyme
IL185556A0 (en) Method and composition for repairing epithelial and other cells and tissue

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 07868423

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 2007868423

Country of ref document: EP